Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 44,590 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired a new position in Amneal Pharmaceuticals, purchasing 44,590 shares valued at approximately $374,000 in the first quarter of 2023.
• Amneal Pharmaceuticals reported earnings of $0.19 per share for the last quarter, exceeding expectations, but the company also indicated a negative return on equity of 188.26% and a negative net margin of 0.46%.
• The stock currently has a consensus rating of "Buy" from analysts, with a target price averaging $11.60, despite a downgrade from "strong-buy" to "buy" by Wall Street Zen.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 44,590 shares of the company's stock, valued at approximately $374,000.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Amneal Pharmaceuticals by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 14,841,969 shares of the company's stock valued at $117,548,000 after purchasing an additional 218,025 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Amneal Pharmaceuticals by 5.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,991,702 shares of the company's stock worth $39,531,000 after acquiring an additional 278,653 shares during the period. Geode Capital Management LLC boosted its stake in shares of Amneal Pharmaceuticals by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 3,813,207 shares of the company's stock worth $30,207,000 after acquiring an additional 26,536 shares during the period. Nantahala Capital Management LLC boosted its stake in shares of Amneal Pharmaceuticals by 37.3% in the fourth quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company's stock worth $29,031,000 after acquiring an additional 995,586 shares during the period. Finally, BlackBarn Capital Partners LP boosted its stake in shares of Amneal Pharmaceuticals by 18.2% in the fourth quarter. BlackBarn Capital Partners LP now owns 2,850,000 shares of the company's stock worth $22,572,000 after acquiring an additional 438,388 shares during the period. Institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals Trading Up 4.1%

Shares of NASDAQ:AMRX traded up $0.34 during mid-day trading on Friday, reaching $8.55. The stock had a trading volume of 1,480,664 shares, compared to its average volume of 1,674,629. The company has a market cap of $2.68 billion, a P/E ratio of 855.36 and a beta of 1.11. Amneal Pharmaceuticals, Inc. has a 1 year low of $6.68 and a 1 year high of $9.48. The business's 50 day moving average price is $7.99 and its 200 day moving average price is $7.96.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. The Goldman Sachs Group assumed coverage on Amneal Pharmaceuticals in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 price objective for the company. Wall Street Zen lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Amneal Pharmaceuticals presently has an average rating of "Buy" and an average price target of $11.60.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.